XML 44 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration and Licensing Agreements (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jul. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
product
item
Sep. 30, 2015
USD ($)
item
Dec. 31, 2014
USD ($)
Jul. 31, 2013
USD ($)
item
Jan. 31, 2013
USD ($)
item
Jun. 30, 2010
USD ($)
Feb. 28, 2009
item
Jun. 30, 2017
USD ($)
item
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
item
Jun. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
item
Collaboration research and licensing agreements                                
Revenue recognized                       $ 13,340,000 $ 66,007,000 $ 17,681,000 $ 73,259,000  
Current portion of deferred revenue $ 95,613,000   $ 95,521,000                 95,613,000   95,613,000   $ 95,521,000
License Agreement | Merck Sharp & Dohme Corp.                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment               $ 1,000,000                
Annual maintenance fees               $ 500,000                
Revenue recognized                       25,000 25,000 50,000 50,000  
Deferred revenue 100,000                     100,000   100,000    
Number of compounds | item               1                
Portion of nonrefundable upfront payment allocated to option               $ 0                
License Agreement | Alexion Pharmaceuticals, Inc.                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment                           2,500,000    
Research term of revenue recognized                 5 years              
Option and license agreement | Alexion Pharmaceuticals, Inc.                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment                 $ 3,000,000              
Milestone payment     $ 5,000,000                          
Number of different target programs | item                 6              
Research license term                 5 years              
Annual maintenance fees                 $ 500,000              
Revenue recognized                       250,000 250,000 500,000 500,000  
Deferred revenue 600,000                     600,000   $ 600,000    
Additional research term                           3 years    
Extension fee                           $ 2,000,000    
Annual maintenance fees payable during any extension of research term                 $ 1,000,000              
2009 Research License and Commercialization Agreement | CSL Limited                                
Collaboration research and licensing agreements                                
Milestone payment   $ 3,500,000                            
Revenue recognized                       0 0 3,500,000 0  
Deferred revenue 0                     0   0    
Number of commercial licenses | item                     1          
Collaboration And License Agreement | Novartis                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment       $ 150,000,000                        
Revenue recognized                       600,000   1,100,000    
Deferred revenue 89,200,000                     89,200,000   89,200,000    
Collaboration And License Agreement | Novartis | Maximum                                
Collaboration research and licensing agreements                                
Potential milestone payment                           $ 2,400,000,000    
Collaboration And License Agreement | Novartis | Bispecific FC Technologies                                
Collaboration research and licensing agreements                                
Number of development stage products | product         2                      
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb14045                                
Collaboration research and licensing agreements                                
Allocation of consideration to deliverables         $ 27,100,000                      
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb13676                                
Collaboration research and licensing agreements                                
Allocation of consideration to deliverables         31,400,000                      
Collaboration And License Agreement | Novartis | Global Discovery Program                                
Collaboration research and licensing agreements                                
Number of bispecific product candidates delivered | item                           0    
Allocation of consideration to deliverables         $ 20,050,000                      
Number of Global discovery programs | item         4                      
Collaboration And License Agreement | Novartis | Global Discovery Program | Maximum                                
Collaboration research and licensing agreements                                
Number of antibody targets for which bispecific technology applied | item         4                      
Collaboration And License Agreement | Novartis | FC Licenses                                
Collaboration research and licensing agreements                                
Research license term                           5 years    
Number of bispecific product candidates delivered | product         4                      
Allocation of consideration to deliverables         $ 11,300,000                      
Collaboration And License Agreement | Novartis | FC Licenses | Maximum                                
Collaboration research and licensing agreements                                
Number of targets against which non-exclusive license is provided | item         10                      
Collaboration And License Agreement | Novo Nordisk                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment             $ 2,500,000                  
Research license term             2 years                  
Revenue recognized                       0 700,000 $ 0 1,400,000  
Deferred revenue 0                     0   0    
Research term of revenue recognized             2 years                  
Collaboration And License Agreement | MorphoSys                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment                   $ 13,000,000            
Milestone payment 12,500,000                              
Revenue recognized                       12,500,000   12,500,000    
Deferred revenue 0                     $ 0   $ 0    
Research and License Agreement 2015 | Amgen, Inc.                                
Collaboration research and licensing agreements                                
Nonrefundable upfront payment           $ 45,000,000                    
Potential milestone payment           $ 1,700,000,000                    
Number of different target programs | item           6                    
Number of previously identified products | item                           3    
Number of bispecific product candidates delivered | item                       0   0    
Substituted candidates | item                       0   0    
Revenue recognized                       $ 0 $ 6,200,000 $ 0 $ 12,500,000  
Deferred revenue $ 12,500,000                     $ 12,500,000   12,500,000    
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           355,000,000    
Allocation of consideration to deliverables                           13,750,000    
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           $ 260,500,000    
Research license term                           3 years    
Allocation of consideration to deliverables                           $ 6,250,000    
Additional research term                           1 year    
Previous targets which bispecific technology will be applied | item           5                    
Research and License Agreement 2015 | Amgen, Inc. | Global Discovery Program                                
Collaboration research and licensing agreements                                
Number of different target programs | item                               3
Number of bispecific product candidates delivered | item                               5
Substituted candidates | item                               1
Development-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           $ 55,000,000    
Development-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           35,500,000    
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           70,000,000    
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           55,000,000    
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           230,000,000    
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                                
Collaboration research and licensing agreements                                
Potential milestone payment                           $ 170,000,000